期刊文献+

唑来膦酸治疗绝经后骨质疏松症后急性发热反应的临床特点 被引量:12

下载PDF
导出
摘要 目的分析应用唑来膦酸治疗绝经后骨质疏松症后患者出现急性发热反应的临床特点及相关因素。方法选取初次使用唑来膦酸治疗绝经后骨质疏松症(Ⅰ型)患者120例,按是否出现急性发热反应分为发热组和对照组。观察发热组发热的特点,比较两组治疗后骨痛缓解时间,治疗前和治疗后1周甲状旁腺素(PTH)、血清碱性磷酸酶(ALP)、降钙素、骨钙素、血清钙等指标,治疗前及治疗后6个月、1年后骨密度(BMD)水平,以及治疗后1年内骨折发生率。结果本组43.6%患者出现急性发热反应;发热组治疗前ALP、骨钙素高于对照组(P<0.05),血清钙低于对照组;治疗前后两组PTH差异无统计学意义(P>0.05);治疗前两组ESR、CRP、降钙素原差异无统计学意义(P>0.05),治疗后1周发热组高于无发热组(P<0.05);治疗前发热组BMD低于对照组(P<0.05),治疗后两组均有提高(P<0.05),发热组提高更明显(P<0.01),治疗后1年发热组BMD提高百分比高于对照组;治疗后1年两组腰椎、髋关节、股骨颈BMD差异无统计学意义(P>0.05)。治疗后1年发热组骨折发生率低于无发热组(P<0.05)。结论初次使用唑来膦酸后出现发热反应的发生率高,多为中等程度一过性发热。治疗前ALP、骨钙素、血清钙、BMD与急性期发热有关。发热者治疗后存在炎性反应。发热者BMD较无发热者提高更快和更明显,且1年后骨折发生率低于无发热者。
出处 《广东医学》 CAS CSCD 北大核心 2014年第6期928-930,共3页 Guangdong Medical Journal
基金 广州市荔湾区科技计划项目(编号:20131215072)
  • 相关文献

参考文献11

  • 1DELMAS P D, BLACK D M, PIERRE D, et al. Once -yearly zoledronic acid for treatment of postmenopausal osteoporosis[ J]. N Engl J Med, 2007, 356 ( 18 ) : 1809 - 1822.
  • 2原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. 被引量:1833
  • 3KAJI I-I, KANATANI M, SUGIMOTO T, et al. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone -cell cultures [ J ]. Horm Metab Res, 2005, 37(10) : 589 -592.
  • 4MASARACHIA P, WEINREB M, BALENA R, et al. Comparison of the distribution of 3H - alendronate and 3H - etidronate in ratand mouse bones[J]. Bone, 1996, 19(3) : 281 -290.
  • 5COXON F P, THOMPSON K, ROELOFS A J, et al. Visualizing mineral binding and uptake of bisphosphonate by osteoelasts and non - resorbing cells[ J]. Bone, 2008, 42(5) : 848 - 860.
  • 6REID I R, GAMBLE G D, MESENBRINK P, et al. Characteriza- tion of and risk factors for the acute - phase response after zole- dronic acid[J]. J Clin Endocrinol Metab, 2010, 95(9) : 4380 - 4387.
  • 7JEAN PIERRE D, PHILIP S, DAVID M, et al. Effect on bone turnover markers of once - yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorti- coids[J]. Rheumatology, 2013, 52(6) : 1058 - 1069.
  • 8GAMSJAEGER S, HOFSTETTER B, ZWETTLER E, et al. Effects of 3 years treatment with once - yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients[ J 1. Osteoporos Int, 2013, 24( 1 ): 339- 347.
  • 9PEPYS M B, HIRSCHFIELD G M. C - reactive protein : a critical update[J]. JClinInvest, 2003, 111(12): 1805 -1812.
  • 10ROELOFS A J, THOMPSON K, EBETINO F H, et al. Bisphos- phonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages [ J ]. Curt Pharm Des, 2010, 16(27) : 2950 -2960.

共引文献1832

同被引文献90

  • 1谢新荣,罗佐杰,秦映芬,梁杏欢,张英.利塞膦酸钠对绝经后骨质疏松症的疗效与安全性研究[J].中国现代医学杂志,2007,17(14):1729-1732. 被引量:6
  • 2Freitas-Neto CA,De Oliveira Fagundes WB,Ribeiro M Jr,et al.Unilateral Uveitis with Vitreous Haze Follow ing Zoledronic Acid Therapy for Osteoporosis[J].Semin Ophthalmol,2013,22(29):68-80.
  • 3Kachnic LA,Pugh SL,Tai P,et al.randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients[J].Prostate Cancer Prostatic Dis,2013,16(4):382-386.
  • 4Rossini M,Zanotti R,Viapiana O,et al.Zoledronic Acid in Osteoporosis Secondary to M astocytosis[J].Am J M ed,2014,3(19):9340-9343.
  • 5Spiegel R,Nawroth PP,Kasperk C.The effect of zoledronic acid on the fracture risk in men with osteoporosis[J].J Endocrinol Invest,2014,37(3):229-232.
  • 6Khajuria DK,Razdan R,Mahapatra DR.The combination therapy with zoledronic acid and propranolol improves the trabecular microarchitecture and mechanical property in an rat model of postmenopausal osteoporosis[J].J Osteoporos,2014,22(30):56-60.
  • 7George S, Weber DR, Kaplan P, et al. Short - Term Safety of Zole- dronic Acid in Young Patients With Bone Disorders : An Extensive Institutional Experience[J]. J Clin Endocrinol Metab, 2015, 100(11) :4 163 -4 171.
  • 8Sieber P, Lardelli P, Kraenzlin CA, et al. Intravenous bisphospho- nares for postmenopausal osteoporosis : safety profiles of zoledronic acid and ibandronate in clinical practice[J]. Clin Drug Investig, 2013,33(2) : 117 - 122.
  • 9Clark EM, Durup D. Inflammatory eye reactions with bisphospho- nates and other osteoporosis medications:what are the risks? [J]. Ther Adv Musculoskelet Dis, 2015,7 ( 1 ) : 11 - 16.
  • 10McClung MR, Grauer A, Boonen S, et al. Romosozumab in post- menopausal women with low bone mineral density[J]. N Engl J Med,2014,370(5) :412 -420.

引证文献12

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部